Icelandic firm Alvotech (Nasdaq: ALVO) and Israel’s Teva Pharmaceutical Industries (NYSE and TASE: TEVA) on Friday announced that the US Food and Drug Administration (FDA) has approved Simlandi (adalimumab-ryvk) injection.
The product is cleared as an interchangeable biosimilar to AbbVie’s blockbuster Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis.
Shares of Alvotech gained almost 3% to $16.03 on the news, while those of Teva rose 4% to 4,974 shekels but fell 1.2% to $12.89 in New York trading.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze